The FDA apparently deems an uncontrolled study acceptable – five months after saying no.
ApexOnco Front Page
Recent articles
Could RO7851624, newly into clinical trials, be RG6735?
Tiragolumab failed the Skyscraper-14 and 03 studies, Roche quietly reveals.
The company claims a 69% response rate with iSCIB1+, but only in a “target population”.
Biopharma's interest in CDH17 and CDH6 continues, courtesy of Lepu and Qilu.
There are questions about vuso-vec’s supporting and confirmatory trials.
Roche’s drug is knocked back in second-line lymphoma, but keeps its third-line nod.
The Bristol/Merck’s drug’s hopes in myelofibrosis have taken a blow.